A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs CPI 613 (Primary) ; Fluorouracil (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 31 May 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 28 May 2019 Planned End Date changed from 1 May 2019 to 1 Aug 2022.
- 01 May 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2019.